2 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Solid Organ Transplant Recipients: new trials by email Literature Review of Solid Organ Transplant Recipients trials Research Report on Solid Organ Transplant Recipients
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Capillary Sampling in Clinical Populations Undergoing Monitoring Blood sampling with capillary sampling device(s) - Chronic Kidney Disease, Autoimmune Diseases | Not yet recruiting | University of Edinburgh | 1000 | 2026-10-01 | 2026-09-03 | |
| Phase I Trial on the Safety of Delayed Infusion of a Naïve T Cell-Depleted Hematopoietic Graft With Memory T Cells in Solid Organ Transplant Recipients Investigational cellular therapy consisting on a HSCT using a graft enriched in CD34+, depleted of naïve T-lymphocytes and supplemented with memory lymphocytes - Solid Organ Transplant Complications, Solid Organ Transplant Recipients | Phase 1 | Recruiting | Francisco Hernández Oliveros | 10 | 2025-06-10 | 2026-05-08 |
| COVID-19 Booster and IIV Schedule in Immunocompromised Hosts Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1 - COVID 19, Influenza | Phase 2 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 660 | 2024-11-20 | 2026-03-10 |
| Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) Sirolimus Topical Cream, Placebo - Solid Organ Transplant Recipients, Skin Cancer | Phase 3 | Active not recruiting | Melanoma and Skin Cancer Trials Limited | 146 | 2024-02-09 | 2025-09-09 |
| TIXAGEVIMAB/CILGAVIMAB Protection of Covid-19 in Transplanted Patients Blood and saliva samplings - Solid Organ Transplant Recipients | Withdrawn | Hospices Civils de Lyon | 2022-02-01 | 2022-09-01 | ||
| Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies self-administered lateral flow assays - Solid Organ Transplant Recipients, Autoimmune Diseases | Completed | Imperial College London | 28411 | 2021-12-07 | 2024-12-09 | |
| Post-Traumatic Stress Symptoms (PTSS) in Transplant Recipients Assessment of adherence, mental health, behavioral, quality of life and biological constructs - Solid Organ Transplant Recipients, Parent(s)/Guardian of Referenced Transplant Recipients | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 124 | 2016-09-01 | 2019-01-07 |
COVID-19 (3) · Autoimmune Diseases (2) · Arthritis, Rheumatoid (1) · Hematologic Neoplasms (1) · Inflammatory Bowel Diseases (1) · Influenza, Human (1) · Renal Insufficiency, Chronic (1) · Skin Neoplasms (1)
Coronaviridae Infections (3) · Coronavirus Infections (3) · Immune System Diseases (3) · Infections (3) · Lung Diseases (3) · Nidovirales Infections (3) · Pneumonia (3) · Pneumonia, Viral (3) · RNA Virus Infections (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Virus Diseases (3) · Neoplasms (2) · Neoplasms by Site (2) · Skin and Connective Tissue Diseases (2)
Blood Specimen Collection (2) · Antigens, CD34 (1) · Mental Health (1) · Quality of Life (1) · Sirolimus (1)
Francisco Hernández Oliveros (1) · Hospices Civils de Lyon (1) · Imperial College London (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Melanoma and Skin Cancer Trials Limited (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Edinburgh (1)
Australia (1) · Canada (1) · France (1) · Spain (1) · United Kingdom (1) · United States (1)
Kiarash Khosrotehrani, MD PhD FACD (1) · Michelle Willicombe, MBBS, MD (1) · Stuart Sweet, M.D., Ph.D. (1)
2025 (1)